Civitas Therapeutics

Civitas Therapeutics was a privately held biopharmaceutical company founded in 2009 (Chelsea/Cambridge, Massachusetts) that developed inhaled therapeutics using the proprietary ARCUS dry-powder pulmonary delivery platform. Its lead program, CVT-301, was an inhaled levodopa therapy for the rapid relief of OFF episodes in Parkinson's disease patients. The company was acquired by Acorda Therapeutics in 2014 for approximately $525 million and no longer operates as an independent entity. It is a life-sciences / drug-development company with no public developer platform, API, SDK, or technical integration surface. Surfaced as a portfolio company of canaan-partners and retained in the API Evangelist network for provenance.

Civitas Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Life Sciences, and Drug Development.

🌐 Visit website 📡 Source on GitHub

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

Company Biopharmaceutical Pharmaceuticals Life Sciences Drug DevelopmentInhalation TherapyParkinson's Disease Acquired

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 2.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/civitas-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: civitas-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/civitas-therapeutics.png
name: Civitas Therapeutics
description: Civitas Therapeutics was a privately held biopharmaceutical company founded in 2009 (Chelsea/Cambridge, Massachusetts)
  that developed inhaled therapeutics using the proprietary ARCUS dry-powder pulmonary delivery platform. Its lead program,
  CVT-301, was an inhaled levodopa therapy for the rapid relief of OFF episodes in Parkinson's disease patients. The company
  was acquired by Acorda Therapeutics in 2014 for approximately $525 million and no longer operates as an independent entity.
  It is a life-sciences / drug-development company with no public developer platform, API, SDK, or technical integration surface.
  Surfaced as a portfolio company of canaan-partners and retained in the API Evangelist network for provenance.
url: https://raw.githubusercontent.com/api-evangelist/civitas-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: Acorda Therapeutics
x-acquired-year: 2014
x-api-surface: none
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Life Sciences
- Drug Development
- Inhalation Therapy
- Parkinson's Disease
- Acquired
tags_raw:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Life Sciences
- Drug Development
- Inhalation Therapy
- Parkinsons Disease
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1